Welcome to our dedicated page for Cardinal Health news (Ticker: CAH), a resource for investors and traders seeking the latest updates and insights on Cardinal Health stock.
Cardinal Health, Inc. (NYSE: CAH) generates a steady flow of news as a major participant in pharmaceutical distribution, medical products manufacturing and distribution, home-health services, and specialty healthcare support. This CAH news page aggregates company press releases and third-party coverage so readers can follow how Cardinal Health’s strategy, operations, and capital decisions evolve over time.
Recent news highlights include updates on financial performance and outlook, such as first-quarter fiscal 2026 results reported via Form 8-K and subsequent press releases, where Cardinal Health discussed revenue growth, segment profit trends, and revised non-GAAP earnings guidance. The company also issues announcements about upcoming earnings releases and webcasts, providing dates and times for quarterly and annual results discussions.
Cardinal Health’s news flow also covers strategic initiatives and acquisitions. For example, the company has reported on its plan and subsequent completion of the acquisition of Solaris Health, described as a leading urology management services organization that adds scale to The Specialty Alliance. Other updates discuss growth in Specialty revenues, expansion of MSO platforms, and the role of BioPharma Solutions and Sonexus™ Access and Patient Support in serving manufacturer partners and patients.
Operational and infrastructure developments are another key news theme. Cardinal Health has announced a new flagship Pharmaceutical and Specialty Solutions forward distribution center in Indianapolis, Indiana, a Consumer Health Logistics Center in Ohio, and new and planned at-Home Solutions distribution centers in Texas and California, all emphasizing automation and technology to support distribution and logistics.
Investors and observers can also find capital markets and governance updates in Cardinal Health’s news, including public offerings of notes to fund acquisitions, quarterly dividend declarations approved by the Board of Directors, and information related to annual shareholder meetings. Bookmark this page to review Cardinal Health (CAH) news across earnings, acquisitions, infrastructure investments, and governance developments in one place.
Cardinal Health has finalized the sale of its Cordis business to Hellman & Friedman for approximately $1 billion. This sale includes the assumption of certain liabilities and retention of specific working capital accounts. CEO Mike Kaufmann emphasized the company's strategic portfolio evaluation approach and commitment to growth, while H&F's CEO Shar Matin expressed excitement about Cordis's independent future and innovative product offerings. Cardinal Health will report its fiscal year 2021 results on August 5, prior to market opening.
AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK) announced a proposed settlement addressing the majority of opioid lawsuits from state and local entities. The settlement, contingent on participation from states and political subdivisions, could provide up to $21 billion over 18 years. Contributions include $6.4 billion from each AmerisourceBergen and Cardinal Health, and $7.9 billion from McKesson. The settlement is seen as a step towards resolving opioid claims, with strong legal defenses maintained in pending litigation if not finalized.
AmerisourceBergen, Cardinal Health, and McKesson have agreed to pay up to $1.179 billion to settle opioid-related claims with New York and its subdivisions, including Nassau and Suffolk Counties. This settlement is part of ongoing negotiations for a broader resolution concerning claims from various states. The distributors will receive claims dismissal in exchange for the settlement amount and associated legal fees. While disputing the allegations, the companies view this as a step toward focusing resources on safe medication delivery and supporting affected communities.
Cardinal Health (NYSE: CAH) has introduced two new solutions aimed at supporting independent pharmacies: NavixRx Compliance Packaging and an E-Commerce Storefront. The NavixRx solution enhances medication adherence by automating compliance packaging for patients taking multiple prescriptions. This service allows pharmacies to outsource packaging, saving time and costs associated with manual processes. The E-Commerce Storefront provides independent pharmacies with online shopping capabilities for over 11,000 products, meeting consumer demand for convenience while maintaining personal pharmacy relationships.
Cardinal Health (NYSE: CAH) will disclose its fourth-quarter and year-end financial results for fiscal year 2021 on August 5, ahead of market opening. A webcast discussing these results will start at 8:30 a.m. Eastern time. The company, which specializes in pharmaceutical distribution and medical products, operates over 40 countries with around 48,000 employees. The webcast and slide presentation will be accessible through the Investor Relations page on their website and available until August 4, 2022.
In a move to boost COVID-19 vaccination rates, four Ohio Managed Care Organizations (MCOs) have partnered with Outcomes, part of Cardinal Health (NYSE: CAH), to utilize local pharmacists for outreach to Medicaid members. The new Needs Immunization service aims to engage over 350,000 eligible participants through personalized consultations, addressing vaccine hesitancy. Pharmacists will connect with members to provide information and, if feasible, administer the vaccine. The initiative reflects the commitment of MCOs to enhance vaccination rates and combat hesitancy in underserved communities.
Cardinal Health (NYSE: CAH) announced the FDA's approval of LYMPHOSEEK® for pediatric use, enhancing lymphatic mapping and sentinel lymph node biopsies in children with solid tumors. This approval allows for improved disease staging in pediatric cancer patients, including those with melanoma and rhabdomyosarcoma. Clinical studies confirm LYMPHOSEEK® is safe for patients aged one month and older, with minimal adverse reactions. This development expands Cardinal Health's radiopharmaceutical offerings and strengthens its position in the precision healthcare market.
Cardinal Health's latest research reveals a growing comfort among oncologists with CAR-T cell therapy, with 60% finding costs reasonable, up from 39% in 2017. The report, based on surveys of 300+ U.S. oncologists, indicates a significant increase in referrals to CAR-T therapy, rising from 54% in 2019 to 91%. Despite these positive changes, challenges remain, including payer approvals and administrative hurdles. The research also highlights the ongoing impact of COVID-19 on cancer screening and the use of telemedicine in oncology.
Cardinal Health (NYSE: CAH) announced an irrevocable early redemption notice for its outstanding notes, totaling $500 million, due June 2022. The affected notes include $237.56 million at a rate of 3.200% and $262.44 million at 2.616%. The redemption date is set for June 15, 2021. The redemption prices will be determined based on specific terms outlined in the indentures, ensuring holders receive the greater of principal or present values of remaining payments. This move reflects Cardinal Health's strategy to manage debt effectively.
Cardinal Health (CAH) reported Q3 FY21 revenue of $39.3 billion, matching last year’s performance. However, GAAP operating earnings fell 16% to $473 million, influenced by a write-down related to the Cordis divestiture. Diluted EPS dropped to $0.40 due to a litigation tax effect. Non-GAAP operating earnings decreased 4% to $689 million, largely from COVID-19 impacts on the Pharmaceutical segment. The company narrowed its fiscal year 2021 EPS guidance to $5.90 to $6.05.